Optimizing Purification Strategies for Non-Traditional mAbs: A Panel Discussion
Join industry specialists as they share their insights, experiences, and strategies to enhance efficiency, reduce costs, and improve product quality in the production of non-traditional mAbs
November 11, 2025
4:00 PM UTC
Sponsored by
November 11, 2025
11:00 AM ET / 10:00 AM CT / 8:00 AM PT / 4:00 PM GMT
In the rapidly evolving field of antibody therapeutics, non-traditional monoclonal antibodies (mAbs) present unique challenges and opportunities in downstream bioprocessing. This roundtable panel discussion will delve into the tools, tips, and key considerations necessary to optimize downstream processes for these innovative therapies to ensure efficient recovery and purification. Join industry specialists as they share their insights, experiences, and strategies to enhance efficiency, reduce costs, and improve product quality in the production of non-traditional mAbs.
Key topics:
Advanced tools and techniques for optimizing purification and recovery.
Best Practices for improving efficiency and product quality.
Real-world examples and learnings from industry specialists.
Speakers
Robert Stairs
Field Applications Staff Scientist
Thermo Fisher Scientific
Robert Stairs is a Field Applications Staff Scientist in the
Bioproduction group at Thermo Fisher Scientific and is responsible for
providing technical support for POROS and CaptureSelect chromatography resins. He
has been a member of the team since 2023. Robert’s career began over 10 years
ago as a part of the Preclinical Manufacturing and Process Development (PMPD)
team at Regeneron Pharmaceuticals in Tarrytown, NY. In his role, he was
responsible for early and late-stage downstream process development,
characterization, scale-up, and technology transfer for monoclonal and
bispecific antibody processes, with a specialization in polishing
chromatography. Following that, Robert supported the process development team
at Applied Genetic Technology Corporation (now Beacon Therapeutics) in Alachua,
FL and was similarly responsible for downstream process development and
technology transfer for AAV based gene therapy programs. Robert earned his
Bachelor of Science in Bioengineering from the University of Maine in Orono,
ME.
Kevin Dornfeld
Principle MSAT Engineer
AGC Biologics
Kevin Dornfeld leads new product introduction for clinical stage molecules and late-stage process transfers as a downstream Principle MSAT Engineer at AGC Biologics. Past roles include downstream PD experience developing and transferring purification processes to support INDs for Mab, Mab Pair, and bispecific antibody projects, MSAT/PD experience with non-antibody processes, and manufacturing operations over the course of 19 years.
James Pullen
Senior Director of Downstream Process Development
FUJIFILM Biotechnologies
James has led the DSP development team for Fujifilm Biotechnologies, UK since 2019. The team are responsible for all aspects of downstream development of clients’ molecules, working with a diverse range of protein-based biologics from both mammalian and microbial feedstocks. They develop robust, scalable processes for transfer to one of their UK or global manufacturing facilities. James has been at Fujifilm Biotechnologies for 14 years, previously holding other roles which have included technical project leader and chromatography subject matter expert. Prior to his industrial career, James completed postdoctoral research at York and Leeds universities focussing on protein structure and function. James holds a PhD and MSci in Chemistry from Imperial College London.
